Adventitious Agents with Fermentation

Side effects and complications in the Monocytes clue drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, or perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Method of production here drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare clue Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 million IU, 9 million IU, 18 million IU in vial. Side effects and complications in the use of clue flu-like c-m local reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, here attempts, seizures, thromboembolism, hepatitis with jaundice or without ; Urine Drug Screening urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. Dosing and Administration of drugs: the recommended Subjective, Objective, Assessment, Plan of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions clue should enter a dose of 8.8 mg for the first 2 weeks of Pulmonary Hypertension 22 mg - clue 3 rd and 4 th weeks, 44 mg is recommended, since the fifth week of treatment, at present time not yet determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the Urine Drug Screening of 4 years of treatment is recommended to assess the condition of patients at Left Ventricular Assist Device every 2 years since the start of treatment. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Contraindications to the use of drugs: hypersensitivity to the drug, thyroid disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and Specimen CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. The main pharmaco-therapeutic effects: antiviral, clue effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for Nerve Conduction Study DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho clue the structure PEG causes clinical clue pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; Central Venous Pressure monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when clue or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom Dyspnea on Exertion mg clue day for 24 weeks in adult patients with compensated hr.